AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CHICAGO -- Atorvastatin at 10 mg/day reduced cardiovascular events in a large randomized primary prevention trial of well-controlled hypertensive patients without dyslipidemia.
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) the incidence of the primary study end point--fatal coronary heart disease and nonfatal MI--was 6.0 events per 1,000 patient-years in the atorvastatin arm and 9.4 per 1,000 patient-years with placebo. The total stroke rate was 5.4 events per 1,000 patient-years with atorvastatin and 7.4 events per 1,000 patient-years with placebo, Dr. Bjorn Dahiof reported at the annual meeting of the American College of Cardiology.
This 36% reduction in relative risk of the primary end point translates to an absolute risk reduction of 3.4 fewer events per 1,000 patient-years of treatment. The 27% reduction in relative risk of stroke translates to an absolute risk reduction of 2.0 strokes per 1,000 patient-years. This substantial clinical benefit for lipid lowering was achieved in a population whose hypertension had been aggressively treated. Blood pressures during ASCOT averaged 138/80 mm Hg.
Financial considerations come into play when considering routine use of statin therapy in hypertensive patients with average or below-average cholesterol levels. Also, the ASCOT population was quite skewed: 95% of the subjects are white, and 81% are male.
ASCOT was a Pfizer-funded trial that enrolled 19,342 hypertensive patients from family practices in the Nordic countries, Ireland, and the U.K. Participants were at moderate cardiovascular risk, with a mean of 3.7 additional cardiovascular risk factors. They ...
Source: HighBeam Research, Statin may curb events in normolipidemic HT. (Primary Prevention...